


Supplementary material

Table 1s. Joanna Briggs Institute Critical Appraisal Checklist for Case Series results for the 50 studies selected.

| Author (year) | Checklist items | | | | | | | | | |
|--------------------------------|-----------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| da Costa L et al. (2018) | No | Yes | Yes | No | No | No | Yes | Yes | No | Yes |
| Martins B 2018 | Yes | Yes | Yes | Yes | No | Yes | No | Yes | Yes | Yes |
| Thomson et al. (2018) | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Yes |
| Ibrahim et al. (2018) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Pittayanon et al. (2018) | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Cahyadi et al. (2017) | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Chen et al. (2017) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Alzoubaidi et al. (2017) | No | Yes | Yes | No | No | No | Yes | Yes | No | Yes |
| Appleby & Hoare (2017) | No | Yes | Yes | No | No | No | No | Yes | No | Yes |
| Thayalasekaran et al. (2017) | No | Yes | Yes | No | No | No | Yes | Yes | No | Yes |
| Alzoubaidi et al. (2017) | No | Yes | Yes | No | No | No | Yes | Yes | Yes | Yes |
| Kwek et al. (2017) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Arena et al. (2017) | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Hagel et al. (2017) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Häberle et al. (2017) | No | Yes | Yes | Yes | No | No | Yes | Yes | No | Yes |
| Eusebi et al. (2017) | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Meng et al. 2017) | No | Yes | Yes | No | No | Yes | No | Yes | Yes | Yes |
| Giles et al. (2016) | No | Yes | Yes | No | No | No | No | Yes | No | Yes |
| Haddara et al. (2016) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Sinha et al. (2016) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Ting et al. (2016) | No | Yes | Yes | No | No | Yes | No | Yes | Yes | Yes |
| Sonthalia et al. (2016) | No | Yes | Yes | No | No | No | No | Yes | No | Yes |
| Sokpon et al. (2016) | No | Yes | Yes | No | No | Yes | No | Yes | No | Yes |
| Pittayanon et al. (2016) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Vivar et al. (2016) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Nasr et al. (2016) | No | Yes | Yes | No | No | No | No | Yes | Yes | Yes |
| Hanna & Wurm (2015) | No | Yes | Yes | No | No | Yes | No | Yes | Yes | Yes |
| Dhesi et al. (2015) | No | Yes | Yes | No | No | Yes | Yes | Yes | No | Yes |
| Ibrahim et al. (2015) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Disney et al. (2015) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Widlak et al. (2015) | Yes | Yes | Yes | No | No | Yes | No | No | Yes | No |
| Dixon et al. (2015) | No | Yes | Yes | Yes | No | Yes | No | Yes | Yes | Yes |
| Malik et al. (2015) | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Jang et al. (2015) | Yes | Yes | Yes | No | No | No | No | Yes | Yes | Yes |
| Szalai et al. (2015) | No | Yes | Yes | No | No | No | No | No | No | No |
| Minelli Grazioli et al. (2015) | No | Yes | Yes | No | No | Yes | Yes | No | Yes | Yes |
| Chen et al. (2015) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Smith et al. (2014) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Masci et al. (2014) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Disney et al. (2014) | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Ali et al. (2014) | No | Yes | Yes | No | No | No | Yes | Yes | Yes | Yes |
| Sagar & Iqbal (2014) | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Barkun et al. (2014) | Yes | Yes | Yes | No | No | Yes | No | Yes | No | Yes |
| Sulz et al. (2014) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Yau et al. (2014) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Ibrahim et al. (2013) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Mangiavillano et al. (2013) | No | Yes | Yes | No | No | Yes | No | Yes | Yes | Yes |
| Holster et al. (2012) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Chen et al. (2012) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Sung et al. (2011) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |

Checklist items: 1. Were there clear criteria for inclusion in the case series?; 2. Was the condition measured in a standard, reliable way for all participants included in the case series?; 3. Were valid methods used for identification of the condition for all participants included in the case series?; 4. Did the case series have consecutive inclusion of participants?; 5. Did the case series have complete inclusion of participants?; 6. Was there clear reporting of the demographics of the participants in the study?; 7. Was there clear reporting of clinical information of the participants?; 8. Were the outcomes or follow up results of cases clearly reported?; 9. Was there clear reporting of the presenting site(s)/clinic(s) demographic information?; 10. Was the statistical analysis appropriate?

General use - Hemostasis



General use - Rebleeding




Fig. 1s Initial hemostasis rates after the general use of TC-325.

Fig. 2s Rebleeding rates after the general use of TC-325.

Peptic Ulcer - Hemostasis




Fig. 3s Initial hemostasis rates after TC-325 use in bleeding from peptic ulcers.

Peptic Ulcer - Rebleeding




Fig. 4s Rebleeding rates after TC-325 use in bleeding from peptic ulcers.

Neoplasm - Hemostasis




Fig. 5s Initial hemostasis rates after TC-325 use in bleeding from neoplasms.

Neoplasm - Rebleeding




Fig. 6s Rebleeding rates after TC-325 use in bleeding from neoplasms.

Esophageal varices - Hemostasis




Fig. 7s Initial hemostasis rates after TC-325 use in bleeding from esophageal varices.

Esophageal varices - Rebleeding




Fig. 8s Rebleeding rates after TC-325 use in bleeding from esophageal varices.

Primay therapy - Hemostasis




Fig. 9s Initial hemostasis rates after TC-325 use as primary therapy.

Primay therapy - Rebleeding




Fig. 10s Rebleeding rates after TC-325 use as primary therapy.

Rescue therapy - Hemostasis




Fig. 11s Initial hemostasis rates after TC-325 use as rescue therapy.

Rescue therapy - Rebleeding




Fig. 12s Rebleeding rates after TC-325 use as rescue therapy.

Anticoagulant - Hemostasis




Fig. 13s Initial hemostasis rates after TC-325 use in patients on anticoagulation therapy.